ELAN Investors Have Opportunity to Join Elanco Animal Health Incorporated Securities Fraud Investigation with the Schall Law Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Elanco Animal Health Incorporated (“Elanco” or “the Company”) (NYSE: ELAN) for violations of the securities laws.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Elanco touted its Zenrelia and Credelio Quattro treatments for animals, which were under review by the FDA. According to the Company, the FDA “has all data necessary to complete its review. All technical sections, including the label, are expected to be approved before the end of June [2024].” The Company announced on June 27, 2024, that it didn’t expect either drug to be approved by the end of June and that Zenrelia would come with a safety warning. Based on these facts, shares of Elanco dropped by 21% on June 27, 2024.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240730888343/en/